Entering text into the input field will update the search result below

More on Ziopharm Q3 results

Oct. 31, 2014 12:49 PM ETAlaunos Therapeutics, Inc. (TCRT) StockBy: Niloofer Shaikh, SA News Editor1 Comment
  • ZIOPHARM Oncology (ZIOP +7.8%) Q3 results: Revenues: $633K (+216.5%); R&D Expense: $9.7M (+56.5%); SG&A: $2.8M (-9.7%); Operating Loss: $(11.9M) (-30.8%); Net Loss: $(6.1)M (+63.5%); EPS: $-0.06 (+70.0%); Quick Assets: $46.1M (-32.4%).
  • No guidance given.

Recommended For You

About TCRT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
TCRT--
Alaunos Therapeutics, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.